Frances M. Platt is Professor of Biochemistry and Pharmacology and Head of the Department of Pharmacology at the University of Oxford, UK. She received her PhD in Animal Physiology from the University of Bath, UK. After completing postdoctoral training at Washington University Medical School, St. Louis, she joined the faculty at the University of Oxford and was the recipient of a five-year Lister Institute Senior Research Fellowship. Her expertise relates to glycosphingolipids (GSL) and in particular glycosphingolipid (GSL) lysosomal storage diseases. She and her colleagues pioneered a novel approach to treat these inherited diseases that led to the development of an approved drug (miglustat) for type 1 Gaucher disease and Niemann-Pick disease type C disease. She was awarded the Alan Gordon Memorial award from the UK Gaucher Association, the Horst-Bickel Award in recognition of her role in developing substrate reduction therapy for lysosomal disorders and the “Above and Beyond” award from National Tay-Sachs and Allied Diseases USA. She was also awarded the Thudichum medal by the Biochemical Society in 2023 for her contribution to sphingolipid research. She serves on the advisory board of multiple lysosomal storage disease charities and organizations (UK and USA). She was elected Fellow of the Academy of Medical Sciences in 2011 and Fellow of the Royal Society in 2021. She is an academic co-founder of the company IntraBio and her translational work has continued as the companies lead drug Aqneursa was FDA approved in 2024 for the treatment of Niemann-Pick disease type C.